Related Experiment Video
Updated: May 31, 2026
08:30
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
Do prostaglandin analogs affect eyelid position and motility?
Michele Altieri1, Ettore Ferrari
1Unit of Ophthalmology, Hospital of Imperia, Imperia, Italy. altieri.ferraris@tin.it
Summary
Topical prostaglandin analogs used for glaucoma do not significantly alter eyelid position or motility. This study found no evidence of eyelid malposition caused by these common eye drop medications.
Area of Science:
- Ophthalmology
- Oculoplastics
- Pharmacology
Background:
- Glaucoma treatment often involves prostaglandin analogs.
- Potential side effects of topical medications on ocular adnexa warrant investigation.
- Eyelid position and motility are crucial for ocular health and function.
Purpose of the Study:
- To investigate the clinical effects of topical prostaglandin analogs on eyelid position and motility.
- To determine if common glaucoma medications cause eyelid malposition.
Main Methods:
- Cross-sectional study comparing 182 patients using prostaglandin analogs (latanoprost, travoprost, bimatoprost) with 191 normal controls.
- Included positive control groups with entropion/ectropion and blepharoptosis.
- Measured upper eyelid parameters (MRD, lid crease, levator function) and lower lid parameters (HLL, LLE).
Main Results:
- No statistically significant differences in eyelid parameters were found between prostaglandin analog users and normal controls.
- No significant variance was observed among subgroups using different prostaglandin analogs.
- Statistically significant differences were noted when comparing prostaglandin analog users to positive control groups with specific eyelid conditions.
Conclusions:
- Topical prostaglandin analogs do not appear to significantly affect eyelid tissues.
- There is no evidence that these medications cause eyelid malposition.
- Further research may explore subtle or long-term effects if any.
Related Concept Videos
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.